Double-blind, randomized, placebo-controlled, parallel-group study of AP30663 administered intravenously for cardioversion in patients with atrial fibrillation

COMMERCIAL CLINICAL TRIAL

Home · MPE05-Translational Research in Cardiovascular Diseases

Clinical trial information

Promoter: SYNEOS HEALTH IVH UK LIMITED (FORMERLY INVENTIV HEALTH CLINICAL UK LTD),
Phase: II
Execution start: 24/06/2019
End of execution: 30/12/2020
IP: LUIS TERCEDOR SANCHEZ